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Does leptin lighten the problem of obesity?
The recent discovery of 'leptin', the product of the mouse obese gene that
appears to be a satiety factor, has electrified the field of obesity research.
Elucidating how the protein works could be a formidable challenge.
Events of the past twelve months have had an explosive
impact on the field of obesity research. This wave of
excitement was triggered by a momentous announce-
ment from Zhang et al. [1] in December 1994. The
authors reported that they had identified the gene
responsible for obesity in one of the most intensively
studied genetic rodent models of the disorder, the ob/ob
mouse, homozygous for a mutant form of the obese (ob)
gene. It turned out that the normal ob gene is expressed
only in fat tissue; it encodes a protein, OB, of molecular
weight -18 kDa, which contains an -2 kDa cleavable
leader sequence, indicating that it is a secreted product.
The ob gene product appears to be highly conserved
among vertebrates, the mouse and human homologues
being 84 % identical at the amino-acid level. The muta-
tion in C57BL/6J strain ob/ob mice introduces a stop
codon into the ob mRNA, causing failure to produce
normal OB protein and, interestingly, a 20-fold over-
expression of the useless mRNA in white fat. A second
mutation is found in ob2J/ob2J mice; in this case, the
mutation occurs in the 5' region of the ob gene and
prevents the synthesis of any ob mRNA [1].
Soon after this breakthrough, three laboratories reported
simultaneously [2-4] that administration of recombinant
OB protein to ob/ob mice corrected both their overeating
(hyperphagia) and their obesity. The protein was accord-
ingly named leptin by Friedman's group, from the Greek
word leptos, meaning thin [3]. Leptin is readily
detectable immunologically as a 16 kDa monomer in
plasma from normal mice and lean, healthy humans [3],
but it cannot be detected in plasma and adipose tissue of
ob/ob mice. Leptin is, however, overexpressed in these
compartments in another strain of genetically obese mice
- those homozygous for a mutant form of the diabetic
(db) gene; leptin is ineffective at reducing the weight of
db/db mice [3,4]. In addition to curbing food intake and
reducing body weight, leptin corrects the hyperglycemia,
hyperinsulinemia, hypometabolism and hypoactivity of
ob/ob mice [2,3]; leptin also reduces the appetite and
weight of mice with diet-induced obesity [4]. Leptin
causes significant loss of body weight and fat content
even in lean mice [2-4], and it is effective whether given
parenterally or injected directly into the lateral ventricle
of the brain [4].
This impressive body of evidence clearly implicates leptin
as an important factor in the regulation of food intake
and general body state ('habitus'). This notion also
appears to fit nicely with the thinking of some far-sighted
early physiologists, who grappled with the question of
how satiety and body weight are controlled. Thus, it was
suspected a half century ago that the central nervous sys-
tem (CNS), in particular the hypothalamus, plays a piv-
otal role in the regulation of body weight. In 1953,
Kennedy [5] went further, postulating that body weight is
regulated through a lipostatic mechanism involving an
interaction between the hypothalamus and some factor in
equilibrium with stored fat. Subsequently, Hervey [6]
surgically linked normal rats, allowing partial exchange of
blood between them ('parabiosis'), and electrically
lesioned the hypothalamus of one member of each pair.
The lesioned animals became hyperphagic and obese,
while their partners developed anorexia and died of star-
vation. Hervey reasoned that, with increasing adiposity, a
humoral factor accumulates and serves to control food
intake through a feedback interaction with the hypothal-
amus; such a factor would, by definition, be ineffective in
the lesioned rats, but it would be passed via the circula-
tion into the non-lesioned parabionts and would suppress
their food intake [6].
With the advent of genetically obese - ob/ob and db/db
- mice, it became possible to test the effect of parabiosis
between the fat and lean animals in various combina-
tions. From a classic study of this type, Coleman [7]
inferred that the ob/ob mouse must lack the circulating
satiety factor, while the db/db strain fails to respond to it,
thus accounting for the similarity of the two phenotypes
when present on the same genetic background [7]. In
light of the newer findings, it seems likely that this long-
sought satiety factor is in fact leptin. If so, the transition
from concept to reality must be regarded as a giant leap
for mousekind. Like all major scientific advances, how-
ever, it brings with it a host of pressing questions. Some
are touched upon below.
Where does leptin work? Current speculation that its
primary site of action is in the hypothalamus (Fig. 1) is
now beginning to receive experimental support. Thus,
Stephens et al. [8] have established that, in association
with its weight-reducing activity, leptin treatment also
normalizes the elevated levels of neuropeptide Y (NPY)
mRNA in the hypothalamus of the ob/ob mouse. Of par-
ticular interest is the preliminary evidence the authors
have provided for the presence of a leptin receptor in the
(rat) hypothalamus (tentatively localized to the arcuate
nucleus), and for the ability of leptin to suppress NPY
release from this site. If these findings are confirmed and
shown to have specificity for leptin at physiological
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concentrations, they could be of great importance, in the
light of the fact that overproduction of NPY has been
strongly implicated in the genesis of rodent obesity [9].
In any event, the task of establishing a leptin-hypothala-
mus linkage will be greatly facilitated when the gene
responsible for the mouse db mutation has been charac-
terized. It will then be necessary to determine whether
the normal DB protein really is a hypothalamic receptor
for leptin, and that the receptor function is defective in
the obese db/db mouse, as presently assumed [1,3,4,8].
What does leptin control? Given leptin's perceived role
as an appetite suppressant, its circulating level would be
predicted to rise as adipose tissue mass expands (see
below) and somehow to diminish the drive to eat (pre-
sumably acting via the hypothalamus). If this is true, and
if leptin is the satiety factor referred to by earlier workers
[5-7], then it presumably functions as part of a long-term
homeostatic mechanism, and not as an acute, meal-
related anorectic agent (the reasoning for this conclusion
is given in an excellent and somewhat prophetic review
by Weigle [10]).
But the situation is clearly more complicated, because
leptin also appears to accelerate the rate of metabolism
and selectively to suppress the synthesis of fat [2-4]. Both
actions can be inferred from studies with thefa/fa Zucker
rat - homozygous for a mutant form of the fatty (fa)
gene - which is thought to be the rat equivalent of the
db/db mouse [11] and, as such, to lack the receptor for
leptin. At only two days of age, the pre-obesefa/fa pups
(identified retrospectively) showed clear signs of defective
thermoregulation and increased adiposity. They also laid
down excess fat when fed an identical diet as their lean
littermates [12,13]. Clearly, if their primary genetic
defect is an inability to respond to leptin, this must mani-
fest itself in a metabolic abnormality that promotes fat
accretion and hypothermia, and which is independent of,
and likely to precede, the associated hyperphagia.
What controls leptin? On teleological grounds, it is
tempting to suggest that insulin plays an important role.
This notion stems from the following considerations. If,
in a broad sense, fat deposition is viewed as one of the
major end points of insulin's anabolic actions, it would
not be unreasonable to suppose that, upon reaching 'full-
ness', fat cells transmit a feedback signal to body centers
controlling fat synthesis and caloric intake. The signal
could be leptin, its site of action the hypothalamus
(and/or elsewhere), and the result a suppression of insulin
secretion and appetite through autonomic control relayed
to the pancreatic cell and elements of the gastrointesti-
nal tract. The following very recent observations would
at least be consistent with such a viewpoint.
The first is that, with the exception of the ob/ob mouse,
all forms of rodent obesity examined to date, both
genetic and non-genetic, exhibit marked elevations in
their plasma leptin levels [3,14,15], and they are all
hyperinsulinemic. Secondly, in most of these models,
Fig. 1. Potential interactions in lipostasis. Hypothetical positive
and negative signaling loops between key organs are depicted.
Broken arrows with question marks indicate uncertainty as to the
site(s) of action of leptin. VLDL, very low density lipoprotein. See
text for details.
including the ob/ob mouse, the mRNA for leptin is over-
expressed in fat tissue [3,14-16]. Although exceptions
have been noted [15], these require confirmation; the
issue of whether leptin expression varies in different fat
depots also remains to be clarified. Thirdly, obesity in
humans, which is also characterized by hyperinsulinemia,
is accompanied by increased leptin mRNA levels and
protein in fat depots and blood, respectively [15,17,18].
Fourthly, in both rodents and humans, leptin production
appears to correlate positively with body fat mass, is sup-
pressed during fasting and increases with refeeding
[14,15,17-20]; insulin secretion has a similar profile.
Importantly, the stimulatory effect of refeeding on leptin
mRNA levels in rat adipose tissue was shown to be
mediated by the attendant increase in circulating insulin
concentrations and not. by the hyperglycemia [19].
Fifthly, leptin mRNA levels are down-regulated in rats
treated with streptozotocin, an effect that is reversed by
insulin treatment of the animals [20]. And lastly, during
differentiation of murine preadipocytes into adipocytes,
synthesis of leptin mRNA occurs concomitantly with the
expression of other insulin-responsive genes [20].
What seems to hold in all of the above situations is the
close association between hyperleptinemia and hyper-
insulinemia, raising the possibility that there exists a
1-cell-adipose tissue axis mediated by insulin and leptin,
as depicted schematically in Figure 1 (whether the other
1-cell product, amylin, is involved remains to be seen).
Should the scheme have validity, defects in any of its com-
ponents could be predicted to lead to obesity. These
would include failure to produce leptin (as in the ob/ob
mouse), resistance to leptin action (as in the db/db mouse),
or some other defect (for example, at the level of the
CNS or the pancreatic cell) that causes oversecretion of
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insulin as an early event [9,21,22]. This last scenario,
especially when coupled with hyperphagia, might be
expected to promote overproduction of very low density
lipoprotein (VLDL) triglyceride by the liver. With time,
excessive delivery of VLDL to fat depots would result in
increased adiposity and secondary hyperleptinemia, the
latter attempting to act as a lipostatic device. As noted
previously [22], chronic exposure of muscle tissue to lipid
substrates is a potentially important factor in the develop-
ment of insulin resistance, a characteristic feature of all
obesity/non-insulin-dependent diabetes syndromes.
The question where leptin fits in the etiology of human
obesity, which almost certainly is polygenic in origin, is
still a matter of speculation. Present indications are that
mutations in the leptin gene are not commonplace in the
human population [23]. Indeed, it is beginning to appear
that the majority of overweight people, just like their
rodent counterparts, overexpress a normal leptin mol-
iecule in proportion to their fat mass [15,17,18]. It might
be argued that such individuals are both insulin and leptin
resistant. What impact this will have on the potential use-
fulness of recombinant leptin for the treatment of human
obesity, should this be contemplated, will undoubtedly be
a much debated issue in the near future.
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